A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain

Supportive Care in Cancer

Volumn 21, Issue 9, 2013, Pages 2557-2563

  Bedard, Gillian ^a   Hawley, Philippa ^b,g   Zhang, Liying ^a   Slaven, Marissa ^c   Gagnon, Pierre ^d,e,f   Bisland, Stuart ^c   Bennett, Margaret ^a   Tardif, Francois ^d,f   Chow, Edward ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f Maison Michel Sarrazin   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Breakthrough pain; Cancer; Patients' perspectives

Indexed keywords

ANALGESIC AGENT; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; OXYCODONE; PARACETAMOL;

ADULT; AGED; ANALGESIA; ARTICLE; AWARENESS; BREAKTHROUGH PAIN; BREAST CANCER; CANADA; CANADIAN; CANCER CENTER; CANCER PAIN; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG TOLERABILITY; ETHNIC GROUP; FEMALE; FUNCTIONAL STATUS; HEALTH SURVEY; HUMAN; JOB PERFORMANCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NOSE DISEASE; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERSONAL EXPERIENCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; SHOPPING; UNSPECIFIED SIDE EFFECT; WORK DISABILITY; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CANADA; DATA COLLECTION; FEAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; PAIN MANAGEMENT; PAIN MEASUREMENT; PALLIATIVE CARE; PATIENT SATISFACTION; YOUNG ADULT;

EID: 84881220652     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1817-4     Document Type: Article

References (18)

1. Burton AW, Fine PG, Passik SD (2012) Transformation of acute cancer pain to chronic cancer pain syndromes. J Support Oncol 10(3):89-95
2. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13(4):331-338
3. Webber K, Davies AN, Cowie MR (2011) Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer 19(12):2041-2046
4. Mercadante S, Ferrera P, Adile C, Casuccio A (2011) Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 42(3):464-469
5. Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72(2):181-190
6. Radbruch L, Torres LM, Ellershaw JE, Gatti A, Luis Lerzo G, Revnic J et al (2012) Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer 20(3):565-573
7. Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15(7):756-763
8. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129-138
9. American Pain F (2011) Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother 25(3):252-264
10. Bhatnagar S, Upadhyay S, Mishra S (2010) Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. J Palliat Med 13(3):291-295
11. Gomez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia Spain. J Pain Symptom Manag 24(1):45-52
12. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 6(2):109-116
13. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41(3):273-281 (Pubitemid 20187930)
14. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6(2):97-108
15. Davis MP (2011) Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother 11(8):1197-1216
16. Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M et al (2012) Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 28(5):859-870
17. Foster D, Upton R, Christrup L, Popper L (2008) Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 42(10):1380-1387
18. Ward SE, Goldberg N, Miller-McCauley V, Mueller C, Nolan A, Pawlik-Plank D et al (1993) Patient-related barriers to management of cancer pain. Pain 52(3):319-324 (Pubitemid 23080550)